Table 1 Single drug treatment against SARS-CoV-2 in vitro
From: Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
Drug candidates | Drug class | Drug indication | CC50 (μM) | IC50 (μM) Plaque assay | IC50 (μM) qRT-PCR |
|---|---|---|---|---|---|
Niclosamide | Anthelminthic agents | Treatment of tapeworm and intestinal fluke infections | 0.29 | 0.049 | 0.043 |
Ivermectin | Anti-parasitic agents | Treatment of onchocerciasis, and other worm infestations | 10.55 | 1.23 | 1.27 |
Chloroquine | Anti-malarial agents | Treatment of malaria, rheumatic diseases and Zika virus infection | 118.20 | 0.83 | 0.89 |